ZSET-845

Cat. No.: HY-U00114: FAQs
Data Sheet Handling Instructions

Molarity Calculator

ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.

For research use only. We do not sell to patients.

ZSET-845 Chemical Structure

CAS No. : 324077-62-5

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Acyltransferase Isoform Specific Products:

View All Isoforms

ACAT1 ACAT2 MGAT2 ACAT

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description	ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.
IC₅₀ & Target	Choline acetyltransferase^[1]
In Vitro	ZSET-845 has no inhibitory action on AChE activity and enhances choline acetyltransferase (ChAT) activity in NB-1 cells^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. ZSET-845 Related Antibodies
In Vivo	Treatment with ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine. Oral administration of ZSET-845 causes an increase in ChAT activity in the hippocampus. In the hippocampus, ZSET-845 (0.01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats^[1]. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	314.38
Formula	C₂₁H₁₈N₂O
CAS No.	324077-62-5
SMILES	O=C1N=C2C=CC=CN2C1(CC3=CC=CC=C3)CC4=CC=CC=C4
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (285 KB) Handling Instructions (2659 KB)
References	[1]. Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. [Content Brief] [2]. Yamaguchi Y, et al. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65. [Content Brief]

Animal Administration
^[1]

Rats: The passive avoidance apparatus consists of a small illuminated chamber and a larger dark chamber. The two chambers are separated by a guillotine door. On the first and second days of testing, each rat is placed in the apparatus and left for 3 min to habituate to the apparatus. On the third day, an acquisition trial is performed. Oral administration of ZSET-845 (0.001, 0.01, 0.1 or 1 mg/kg), donepezil or tacrine (0.01, 0.1, 1 or 10 mg/kg) is given 60 min before the acquisition trial. Scopolamine (2 mg/kg) is intraperitoneally (i.p.) injected 20 min before the acquisition trial. Matched control rats received vehicle only^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. [Content Brief]

[2]. Yamaguchi Y, et al. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65. [Content Brief]

ZSET-845 Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ZSET-845324077-62-5ZSET845ZSET 845AcyltransferaseDiacylglycerol acyltransferaseDiglyceride acyltransferaseacyl-CoA:cholesterol acyltransferasemono- acylglycerol acyltransferaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #